New drug combo shows promise in shrinking esophageal tumors before surgery

NCT ID NCT07457528

Recruiting now Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Mar 10, 2026 · Last updated Apr 29, 2026 · Updated 8 times

Summary

This study is for people with a type of esophageal cancer that can be removed with surgery. Researchers are testing whether adding two drugs (serplulimab and nimotuzumab) to standard chemoradiation can improve results. About 46 participants will receive the combination treatment before surgery, and doctors will check how much the tumor shrinks. The goal is to see if this approach is safe and more effective than standard therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, Tianjin Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA